MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD – Get Rating)’s share price fell 4.6% during trading on Wednesday . The stock traded as low as $1.62 and last traded at $1.66. 305,262 shares traded hands during mid-day trading, a decline of 34% from the average session volume of 461,875 shares. The stock had previously closed at $1.74.
MyMD Pharmaceuticals Trading Down 4.6 %
The firm has a fifty day simple moving average of $1.80 and a 200 day simple moving average of $1.74. The stock has a market cap of $65.52 million, a price-to-earnings ratio of -4.61 and a beta of 2.19.
Institutional Investors Weigh In On MyMD Pharmaceuticals
A number of large investors have recently bought and sold shares of MYMD. Renaissance Technologies LLC acquired a new position in shares of MyMD Pharmaceuticals in the 3rd quarter valued at $27,000. Jane Street Group LLC acquired a new stake in MyMD Pharmaceuticals during the 2nd quarter worth $28,000. Praetorian Wealth Management Inc. raised its stake in MyMD Pharmaceuticals by 66.7% during the 4th quarter. Praetorian Wealth Management Inc. now owns 25,000 shares of the company’s stock worth $29,000 after buying an additional 10,000 shares during the period. Commonwealth Equity Services LLC acquired a new stake in MyMD Pharmaceuticals during the 1st quarter worth $29,000. Finally, Two Sigma Investments LP acquired a new stake in shares of MyMD Pharmaceuticals in the 4th quarter valued at about $35,000. 10.22% of the stock is currently owned by institutional investors.
MyMD Pharmaceuticals Company Profile
MyMD Pharmaceuticals, Inc, a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression.
Further Reading
- Get a free research report on MyMD Pharmaceuticals from StockNews.com
- Smartsheet Investors’ Hasty Exit Can Be Your Gain
- Agilent Technologies Stock: Ready to Rise off the Floor
- Oilfield Services Growing Faster Than Wider Energy Sector
- La-Z-Boy Reclines To The Buy Zone As Industry Normalizes
- Five stocks we like better than MyMD Pharmaceuticals
Receive News & Ratings for MyMD Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyMD Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
